Kuehne+Nagel and Moderna clinch deal for vaccine distribution

K+N will provide warehousing for the Moderna vaccine at its European pharma hub and will distribute the vaccine via road and air.

Air & Cargo Services air cargo Air Cargo Asia air cargo freight Air Forwarding air freight Air Freight Asia Air Freight Logistics air freighter air freighting Air Logistics Asia Air Shipping Asia airlines cargo airways cargo asia cargo news cargo aviation Kuehne+Nagel Moderna pharma cargo vaccine logistics

Kuehne+Nagel road logistics Courtesy of Kuehne+Nagel

Kuehne+Nagel has finalised a deal that will see the freight forwarder supporting the supply chain and distribution of Moderna’s Covid-19 vaccines.

The logistics provider will support the worldwide distribution of vaccine doses from the US-based biotech firm’s facility in Europe to markets in Europe, Asia, Middle East and Africa, and parts of the Americas.

K+N will provide cold storage warehousing for the vaccine at its pharma hub in Europe and will use its network to distribute the vaccine via road and air. Product integrity at the required temperature of -20°C will be maintained at all stages of transport and storage, it noted.

Also read: AirBridgeCargo, Kuehne+Nagel run pharma charter service from Leipzig to Guangzhou

“With today’s announcement, we take on the responsibility to distribute Covid-19 Vaccine Moderna around the world,” said Robert Coyle, senior vice president, pharma & healthcare.

“We have invested in our pharma & healthcare network and our global team of experts for decades – we are ready now, for when it matters the most,” he added.

Kuehne+Nagel said its logistics subsidiary, QuickSTAT, has been an integral part of Moderna’s vaccine supply chain during the phase II and phase III clinical trials in the US.

Following the recent approvals, this is another step closer to resolving the pandemic and an exciting time for both our companies and everyone involved,” shared Dan Staner, vice president and head of EMEA at Moderna.

The announcement follows the conditional marketing authorisation granted to Moderna by the EU’s medicines regulator.

Leave a Reply

Your email address will not be published. Required fields are marked *